Combination Therapy With Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation

NCT02474927 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Lung Transplant Rejection

Interventions

DRUG: Carfilzomib

Sponsor

John F. McDyer, MD